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Abstract 
The role of the Pax3 gene in embryonic development of pigment cells is well characterized. 
By contrast, the function of Pax3 in melanoma development is controversial. Indeed, data 
obtained from cultured cells suggest that PAX3 may contribute to melanomagenesis, and 
PAX3 is found overexpressed in melanomas but also in nevi compared to normal skin 
samples. Pax3 homozygous loss of function is embryonic lethal. In order to assess the role of 
Pax3 in melanoma development in vivo, we analyzed Pax3 haploinsufficiency in a mouse 
model of melanoma predisposition.  
The Pax3GFP/+ knock-in reporter system was combined with the Tyr::NRASQ61K; Cdkn2a-/- 
mouse melanoma model. Melanoma development was followed over 18 months. 
Histopathological, immunohistochemical and molecular analyses of lesions at different stages 
of melanoma progression were performed. Fluorescence-activated cell sorting on GFP of cells 
from primary or metastatic melanoma was followed by ex vivo transformation tests and in 
vivo passaging. 
We report here that Tyr::NRASQ61K; Cdkn2a-/-; Pax3GFP/+ mice developed metastasizing 
melanoma as their Tyr::NRASQ61K; Cdkn2a-/- littermates. Histopathology revealed no 
differences between the two genotypes, although Pax3 mRNA and PAX3 protein levels in 
Pax3GFP/+ lesions were reduced by half. Pax3GFP allele proved a convenient marker to identify 
and directly sort heterogeneous populations of melanoma cells within the tumor bulk at each 
stage of melanoma progression.  
This new mouse model represents an accurate and reproducible means for identifying  
melanoma cells in vivo to study mechanisms of melanoma development.  
 
Key words: PAX3, mouse melanoma models, primary culture, direct FACS-sorting, 
immunohistology.
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Introduction 
The Paired box 3 (PAX3) transcription factor is a key regulator of pigment cells development 
during embryogenesis [1]. Pax3 gene is expressed in melanoblasts and melanocytes. Several 
pieces of evidence suggest that Pax3 may be involved in the formation of melanomas. Pax3 is 
expressed by neoplastic melanocytes in nevi and melanomas [2]. PAX3 transcription factor 
was shown to modulate mRNA expression levels of genes known to be involved in 
differentiation, proliferation and survival of melanoma cultured cells [3]. In addition, 
silencing Pax3 using RNA interference was shown to inhibit proliferation, and induce 
terminal differentiation and apoptosis following activation of caspase-3 and p53 in melanoma 
cells [4-6]. More recently, Pax3 silencing was reported to inhibit invasiveness of melanoma 
cells in culture [7] as well as the growth of melanoma cells with acquired resistance to 
vemurafenib [8]. PAX3 is also expressed in muscle progenitor cells before myogenic 
transcription factors, such as MyoD, Myogenin, and Myf5 and gradually declines during 
muscle differentiation. Interestingly, human PAX3 gene	  is re-expressed in some cancers such 
as rhabdomyosarcomas and Ewing’s sarcoma, suggesting that PAX3 may play a role in 
human malignancies [9]. To test the role of Pax3 in melanocyte transformation to melanoma, 
we analyzed the effect of haploinsufficiency for Pax3 in a model of cutaneous metastasizing 
melanoma. We took advantage of Tyr::NRASQ61K; Cdkn2a-/- mice that carry a transgene for a 
dominant-active NRAS targeted to the melanocyte lineage by the Tyrosinase promoter (Tyr)  
and a deletion at the Cdkn2a locus which encodes the two tumor suppressor proteins p16INK4A 
and p14ARF. These mice develop pigmented melanomas that acquire the ability to metastasize 
[10]. We have recently proposed a histopathological classification for melanocytic lesions in 
this model [11]. Tyr::NRASQ61K; Cdkn2a-/- mice were mated with Pax3GFP/+ mice. In 
Pax3GFP/+ mice, the reporter gene GFP is inserted into the first exon of the Pax3 gene, leading 
to a null allele with GFP expression in PAX3-positive cells [12]. Our hypothesis was that 
	  
	  
	  
5	  
reduced Pax3 expression in Pax3GFP/+ mice, compared to Pax3+/+ homozygous mice, would 
delay melanocyte transformation to melanoma in Tyr::NRASQ61K; Cdkn2a-/- mice, thus 
slowing down the metastatic process. To our surprise, Tyr::NRASQ61K; Cdkn2a-/-; Pax3GFP/+ 
mice developed cutaneous metastasizing melanoma with clinical features similar to the ones 
of their Tyr::NRASQ61K; Cdkn2a-/-; Pax3+/+ littermates. We further tested whether the Pax3GFP 
allele could be used as a convenient marker to identify and sort melanoma cells within the 
tumor bulk. Primary cultures of melanocytic cells, from non-transformed melanocyte to 
melanoma cells of various stages of progression, were obtained. Sorted cells kept specific 
essential attributes of their stage of origin. Therefore the Pax3GFP allele provides a usable 
marker for melanoma cells in the mouse. 
 
Methods 
Mice and genotyping. Transgenic Tyr::NRASQ61K were produced at the Swiss Institute for 
Experimental Cancer Research [10]; Cdkn2a-/- at the Albert Einstein College of Medicine [13] 
and Pax3GFP/+ mice at the Institut Pasteur [12]. These three mouse lines have been 
backcrossed onto the C57BL/6J background for more than 15 generations. Eight week-old 
C57BL/6J females were used for intra-venous injection of 106 syngeneic tumoral cells.  
(agreement n° 16 notice 14/02/12-4). Details on mice genotyping can be found in 
supplementary material. 
Histologic analysis and immunofluorescence in mouse samples. Complete necropsy, 
systematic histopathologial analysis with routine hematoxylin-eosin-saffron (HES) staining 
and classification of melanocytic lesions were performed on Tyr::NRASQ61K; Cdkn2a-/-; 
Pax3GFP/+ (N=33), and Tyr::NRASQ61K; Cdkn2a-/-; Pax3+/+ (N=65) adult mice, as described 
[14]. Briefly, grossly not remarkable cutaneous pigmented lesions with benign features were 
classified as nevi. Microscopically, they consisted of dermal stellate shaped and heavily 
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pigmented melanocytes in the vicinity of hair follicles. Early nevi were composed of 
melanocytes with small nuclei separated by collagen bundles. Late nevi had higher cellular 
density, fewer collagen bundles and displayed larger yet bland nuclei. Grossly visible nodules 
forming plaques <2mm were identified as atypical nevi. These lesions were ill demarcated 
and exhibited features suggestive of malignancy like moderate to low nuclear-cytoplasmic 
ratio (NCR), larger nucleoli, pleomorphism and rare mitoses. Cutaneous melanomas were 
usually larger than 2mm. Melanomas were located in the dermis and hypodermis. They 
displayed (i) high cellular density, (ii) frank nuclear atypias, (iii) increased number of mitosis 
and (iv) usually low pigmentation. Necrosis was common. Lung metastases were multifocal 
and composed of variably pigmented and pleomorphic cells arranged around vessels [14]. 
Direct fluorescence was detected in frozen sections with DAPI counterstaining upon 
overnight fixation in 0.5% paraformaldehyde in 4% sucrose of skin and lung. For 
immunofluorescence analyses, antigen retrieval was performed in citrate buffer pH 6 for 30 
min in a water-bath. Blocking was performed for 1h at RT in 10% normal goat serum, bovine 
serum albumin 1% in PBS. Primary antibodies (list in supplementary material) were 
incubated overnight at 4°C. Secondary Alexa-fluor antibodies (Invitrogen, 1:400) were 
incubated for 1h at RT, with Alexa-fluor 488 reserved exclusively for the anti-GFP antibody 
as endogenous GFP was not completely lost with fixation. The sections were then mounted in 
Vectashield (Vector, Abcys, Courtaboeuf, France). Sections were examined with a Zeiss Axio 
Observer Z1M ApoTome microscope (Carl Zeiss S.A.S.; Le Pecq, France). Images were 
processed with the AxioVision computer program version 4.6 (Carl Zeiss) and colors could be 
changed. Figures are representative of the skin samples evaluated (N>8 for each line). All 
images are individual sections of z series stack. Final figures were assembled with Adobe 
Photoshop CS6 (Adobe Systems; USA). 
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RNA extraction and RT-qPCR. RNA extractions were performed on formalin-fixed, 
paraffin-embedded (FFPE)	   melanoma samples collected from Tyr::NRASQ61K; Cdkn2a-/-; 
Pax3+/+ (N=5) or Tyr::NRASQ61K; Cdkn2a-/-; Pax3GFP/+ (N=5) mice using NucleoSpin FFPE 
RNA kit (Macherey-Nagel, Hoerd, France). Reverse transcriptions were performed using 
Maxima First Strand cDNA Synthesis kit (Fermentas, Thermo fisher, Villebon s/Yvette, 
France). qPCR were performed using Maxima SYBR green qPCR kit (Fermentas) on a Roche 
Light Cycler Carousel-based system (Roche). All methods followed manufacturer’s 
instructions qPCR primers are available in supplementary material. qPCR experiments were 
carried out at least twice in triplicates. 
Protein extractions and western-blot analyses. Before loading on 10% acrylamide gels, 
proteins were denatured 5 min at 95°C. Transfer was realized on PVDF membrane. The 
primary antibodies were rabbit anti-PAX3 (Zymed, Invitrogen, 1:1000, Cergy Pontoise, 
France,) and mouse anti-α-tubulin (eBioscience, 1:2000, Paris, France). Quantification was 
made using ImageJ software. 
Fluorescent activated cell sorting (FACS). FACS-sorting of melanocytes was performed as 
previously described [15]. Primary cutaneous melanomas and metastases from lymph nodes 
or lungs sampled at necropsy were finely chopped and incubated for 20 min at 37°C under 
agitation in collagenase type IV (Gibco Invitrogen Cell Culture, Cergy Pontoise, France), 
liberase TM (Roche, Meylan, France) and DNAse (Epicentre, Tebu-bio, Le Perray, France). 
Supernatant was neutralized in DMEM medium containing 10% FCS and remaining tissues 
were incubated in a new digestion mix for 10 additional minutes. Cell suspensions were 
filtered, centrifuged and resuspended in PBS, 2mM EDTA. All acquisitions and data analyses 
were performed with a MoFlo XDP Flow Cytometer (Beckman Coulter, Villepinte, France) 
interfaced to FlowJo software. Cells were gated for single events and viability, then sorted on 
GFP expression. Three to six samples were FACS-sorted for each stage of melanoma. 
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Cell culture and immunofluorescence. FACS-sorted melanocytes were cultured without 
feeder cells as described [15]. Experiments herein used cells trypsinized up to 5 passages. For 
immunofluorescence, cells were plated onto cover slips for 24 h, then fixed 15 min with 2% 
paraformaldehyde, permeabilized 10 min with ice-cooled methanol and labeled as described 
above. 
Soft agar Assay. Approximately 5 × 104 cells/ mL and 5 × 105 cells/ mL were seeded in 
quintuplicates in 96-well plates with Seaplaque agar, and observed 12 days later. The assay 
was performed twice. 
Modified Boyden chamber assay. Approximately 2 × 104 cells were placed onto Matrigel 
coated cell culture inserts (0.8 µM pore, R&D-Systems) in quintuplicates. These inserts were 
suspended over 24-well plates containing DMEM and 1% FCS, as chemoattractant. Twenty 
four hours later, the cells on the underside of insert filters were fixed, stained with cresyl 
violet and counted under a bright-field microscope. The assay was performed twice. 
Statistical analysis. All error bars in the figures represent standard error of the mean. 
Student's t-test or nonparametric Mann-Whitney U test were used to assess differences 
between groups. A P-value <0.05 was considered as statistically significant. 
 
Results  
Generation of Tyr::NRASQ61K; Cdkn2a-/-; Pax3GFP/+ mice 
Pax3GFP/+ mice exhibit a coat color characterized by a variably-sized white belly spot, with 
white tail tip and paws reflecting defective migration of melanoblasts during embryogenesis 
(Fig. 1a), as observed in heterozygous Splotch (Pax3Sp/+) mice [16]. We mated Pax3GFP/+ 
knock-in mice with Tyr::NRASQ61K; Cdkn2a-/- mice that exhibit skin hyperpigmentation (Fig. 
1b). Tyr::NRASQ61K; Cdkn2a-/-; Pax3GFP/+ mice  exhibited a compound phenotype with skin 
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hyperpigmentation due to transgenic N-RASQ61K expression, and a white belly spot and white 
paws caused by Pax3 haploinsufficiency (Fig. 1c).  
Melanoma development in Tyr::NRASQ61K; Cdkn2a-/-; Pax3GFP/+ mice  
Mice were examined for melanocytic cutaneous lesions. All mice developed the spectrum of 
dermal melanocytic proliferation previously identified in Tyr::NRASQ61K; Cdkn2a-/-; Pax3+/+ 
individuals [14]. Grossly visible nodules and plaques (<2mm) could be observed in 80% of 
the animals of both genotypes (Fig 2a). Twenty two out of 65 Tyr::NRASQ61K; Cdkn2a-/-; 
Pax3+/+ control mice presented cutaneous nodules larger than 2mm wide compared to 11 out 
of 33 Tyr::NRASQ61K; Cdkn2a-/-; Pax3GFP/+ mice (Fig. 2b). Focal and distant metastases were 
detected upon complete necropsy in mice with both genotypes (Fig. 2c, d). The incidence of 
lung metastases was similar in both genotypes: 7 out of 22 control mice, and 4 out of 11 
Tyr::NRASQ61K; Cdkn2a-/-; Pax3GFP/+ mice developed lung metastasis (Student’s t test; 
P>0,05). Systematic histopathological analysis was performed on melanocytic lesions from 
littermates with both genotypes with criteria summarized in the Methods section. Figure 2 e-g 
shows representative fields of nevi (Fig. 2e) melanomas (Fig. 2f) and lung metastases (Fig. 
2g) which did not differ between both genotypes. No differences in melanoma clinical 
features – color, size and sites – were identified. No significant differences in either latency or 
incidence (Mann-Whitney test; P>0,05) were seen between the two genotypes over 18 months 
(Fig. 2h). To summarize, clinical and histopathological features of the Tyr::NRASQ61K; 
Cdkn2a-/- melanoma model were independent of Pax3 gene dosage. 
Since clinical characteristics were alike in both genotypes, we investigated the oncogenic 
driving molecular pathway of the model. NRASQ61K causes constitutive activation of the 
NRAS protein leading to extracellular signal-regulated kinase (ERK) activation. Phospho-
ERK signal was detected in melanomas from Tyr::NRASQ61K; Cdkn2a-/-; Pax3GFP/+ and 
control mice. This suggests that the ERK pathway was not altered in Pax3GFP/+ transformed 
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melanocytes (Fig. S1). To further explore if PAX3 was necessarily increased in melanomas, 
we tested whether melanoma lesions had developed by upregulation of the Pax3 wild type 
allele. Pax3 mRNA and PAX3 protein levels were evaluated in primary melanomas from 
Tyr::NRASQ61K; Cdkn2a-/-; Pax3GFP/+ and control mice. Quantification confirmed a reduction 
by half of the amounts of Pax3 mRNA and PAX3 protein in melanomas from Tyr::NRASQ61K; 
Cdkn2a-/-; Pax3GFP/+ mice compared with the controls (Student’s t test; P<0.05; Fig. 2i, j). 
These data indicate that no compensation from the wild type allele took place in 
Tyr::NRASQ61K; Cdkn2a-/-; Pax3GFP/+ mice melanomas. Altogether, Pax3 appears to be 
haplosufficient for melanoma development in the Tyr::NRASQ61K; Cdkn2a-/- model.  
Pax3GFP allele and melanoma cells sorting by FACS 
We have recently shown that the Pax3GFP allele provides a valuable reporter to identify 
melanocytes and their precursors in hair follicle biopsies based on GFP expression [15]. We 
used the direct fluorescence of GFP expression in melanomas from Tyr::NRASQ61K; Cdkn2a-/-
; Pax3GFP/+ mice to identify transformed melanocytes. The GFP signal was strong in the 
nucleus, and fainter in the cytoplasm of melanoma cells (Fig. 3b) as in melanocytes (Fig.3a). 
In melanoma sections, PAX3 and GFP colocalized in the same cells by immunofluorescence 
(Fig. 3c, d).  
To obtain pure primary cultures of melanoma cells, primary melanoma (PM), locoregional 
metastasis (LRMet), and distant metastasis (DMet) were removed from Tyr::NRASQ61K; 
Cdkn2a-/-; Pax3GFP/+ mice, the tumoral cells were dissociated and melanocytic cells were 
FACS-sorted on GFP expression. As controls, primary cultures of FACS-sorted melanocytes 
were isolated from the back skin of pups. Melanoma primary cultures were morphologically 
diversified, reflecting the heterogeneity of melanoma cells in tumor bulks (Fig. 4a). Cells 
were variably pigmented. Constitutive ERK activation was detected in all cells of primary 
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cultures from Tyr::NRASQ61K; Cdkn2a-/-; Pax3GFP/+ mice (Fig. S2) indicating that Pax3GFP/+ 
cells were melanocytic cells as they expressed the Tyr::NRASQ61K transgene. 
Functional characterization of FACS-sorted melanoma cells  
In order to determine if the isolation technique of melanoma cells from the Tyr::NRASQ61K 
Cdkn2a-/-; Pax3GFP/+ model during the metastatic process was accurate, primary cultures 
established from PM, LRMet, and DMet tissues were analyzed in detail. Their transformed 
properties were evaluated both in vitro and in vivo. Whereas control primary cultures of 
melanocytes from neonatal skin did not proliferate in soft agar, FACS-sorted melanocytic 
cells from all tested tumors resulted in colonies within 12 days indicating anchorage-
independent proliferation (Fig. 4b). Cell migration and invasion was measured using a 
modified Boyden chamber assay. FACS-sorted melanocytic cells originating from the tumors 
were able to migrate by contrast with melanocytes from healthy skin (Student’s t test; p<0.05, 
Fig. 4c). So far, the in vitro tests could distinguish only control non-transformed melanocytic 
cells from the transformed ones. To test their invasive capacities in vivo, FACS-sorted 
melanocytic cells from PM, LRMet, and DMet tissues were retro-orbitaly injected to 
syngeneic C57BL/6J mice. Two weeks later, the injected mice were euthanized and their 
lungs were examined. Pigmented nodules were visible in lungs from mice receiving DMet 
cells. The entire lungs were sliced and observed under the microscope. Some micrometastasis 
were pigmented but all of them were PAX3 positive and GFP-positive. GFP-positive 
micrometastases were found in 1 out of 3 C57BL/6J mice injected with PM cells and in 4 out 
of 4 C57BL/6J mice injected with either LRMet or DMet cells (Figure 4d). Thus primary 
melanoma cells could be effectively distinguished from more aggressive metastatic melanoma 
cells. All in all, the Pax3GFP allele was useful to sort melanocytic cells from cutaneous tumors 
and metastasis.  
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Discussion 
Cell lineage fluorescent reporters have proved useful to visualize cells in the mouse under 
different physiopathological conditions (http://www.gensat.org/index.html). The Pax3GFP 
allele provides a valuable fluorescent reporter to identify melanocytic cells in skin biopsies 
[15]. To test whether it is also a valuable marker of melanocytic cells in tumors, 
Tyr::NRASQ61K; Cdkn2a-/- and Pax3GFP/+ mice were bred to produce compound mutant mice. 
The hyperpigmentation/white bellied phenotype of the triple mutants suggests an absence of 
genetic interaction between Pax3 and Tyr gene regulation. Noteworthy, Pax3 transcripts are 
first detected at day 8.5 in the embryo in the dorsal-most cells of the neuroepithelium [17], 
whereas the Tyr gene is expressed at later stages around midgestation [18]. PAX3 is not 
known to participate in the regulation of Tyr transcription either directly [19] or indirectly [4]. 
Considering the reports on PAX3 involvement in the proliferation, migration and invasiveness 
of melanocytes from pigmented tumors in vitro, we expected modifications of 
melanomagenesis parameters in the Tyr::NRASQ61K; Cdkn2a-/- model [14]. However, neither 
clinical nor histological changes were detected in the tumors of Tyr::NRASQ61K; Cdkn2a-/-; 
Pax3GFP/+ mice compared to their Pax3+/+ littermates. These results infirm the hypothesis of 
an effect of PAX3 levels in the differentiation of melanoma cells. Comparable metastatic rate 
suggests no overall change in cell migration upon removing one functional copy of Pax3 
gene, implying that Pax3 is haplosufficient for tumor development. Alternatively, PAX3 
could have a stimulatory effect on melanoma through a MDM2-mediated ubiquitination of 
p53 as shown in mouse embryonic stem cells induced to form neuronal precursors [20]. In 
that case, the present model with Cdkn2a locus inactivation would not reveal such 
interactions. However, melanoma development in Cdkn2a+/- mice did not show clinical 
differences either (data not shown). 
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Yet some reports seem to be in accordance with our results. In fact, complex regulation of 
PAX3 transcriptional activities have been described which could explain a lack of phenotype 
of Pax3GFP/+ on melanoma initiation, progression and metastasis. First, the histone deacetylase 
HDAC10 has been shown to relieve repression of PAX3 on MITF, TRP-1 and DCT promoters 
[21] suggesting that deacetylation of PAX3 could be an additional layer of melanomagenesis 
regulation. Second, Bonvin et al. have shown that PAX3 is an activator of BRN2 expression, 
which is considered to be a regulator of melanomagenesis. However the range of PAX3 
reduction obtained herein could still not affect BRN2 levels which were shown not to be 
particularly sensitive to PAX3 levels [7]. Third, interestingly enough, in human melanoma 
cell lines, levels of PAX3 and MITF were found to vary from 15 to 100 fold [22] suggesting 
that transformation is not dependent on these levels. Fourth, only 60% of human melanoma 
tissue samples showed PAX3 expression by in situ hybridization [6] accounting for an inter-
individual variation in PAX3 expression which, in light of the present data, would confirm 
PAX3 haplosufficiency for melanomagenesis. 
Cell isolation from cutaneous and metastatic lesions in Tyr::NRASQ61K; Cdkn2a-/-; Pax3GFP/+ 
mice and identification of melanocytic cells were particularly efficient when the cells were 
sorted on GFP expression. Importantly, Cdkn2a locus deletion avoided senescence of the 
primary cultures [23]. At the early passages high cell heterogeneity corresponded probably to 
the in vivo variety of cellular types, including the so called cancer stem cells, within the tumor 
bulk. This material would be a useful tool for new drug screening with the ease of in vitro 
testing and the accuracy of in vivo biological heterogeneity.  
Conclusion 
All in all, the primary cultures from FACS-sorted GFP-positive cells presented the properties 
of their tumoral stage of origin. The Pax3GFP allele proved to be a sensitive fluorescent 
reporter of normal and tumoral melanocytic lineage in vitro and in vivo ([15] and herein). 
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Altogether the Tyr::NRASQ61K; Cdkn2a-/-; Pax3GFP/+ model allows easy identification of 
melanocytes and melanoma cells within tissues without interfering with tumor progression. 
Considering that a single murine melanoma model cannot reflect all types of human disease, 
and provided that Pax3 haplosufficiency occurs in other melanoma models, use of the 
Pax3GFP allele will be a helpful and powerful tool to study mechanisms of melanoma 
development in vivo in different genetic contexts.  
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Figure legends  
Figure 1. Tyr::NRASQ61K; Cdkn2a-/-; Pax3GFP/+ mice  
a-c: Phenotype of (a) Cdkn2a-/-; Pax3GFP/+ mice presenting a white belly spot, white feet and 
tail tip (arrows), (b) Tyr::NRASQ61K; Cdkn2a-/-; Pax3+/+ littermates with hyperpigmented skin 
(arrowheads) and (c) Tyr::NRASQ61K; Cdkn2a-/-; Pax3GFP/+ littermates harboring a compound 
phenotype (arrows, arrowheads).  
 
Figure 2. Melanomagenesis in Tyr::NRASQ61K; Cdkn2a-/-; Pax3GFP/+ mice  
a-d: a Tyr::NRASQ61K; Cdkn2a-/-; Pax3GFP/+ mouse with cutaneous nodules identified as 
atypical nevi (a, white arrow heads), melanoma (b, white arrow), local metastasis in the 
lymph node (c, white arrow) and lung metastasis (d). Red asterisk (a-c) indicates the Pax3 
haploinsufficiency for coat color. e-g: Histological features (HES staining) of melanocytic 
nevus (e), primary melanoma (f) and lung metastasis (g) in Tyr::NRASQ61K; Cdkn2a-/-; 
Pax3+/+ control (1) and Tyr::NRASQ61K; Cdkn2a-/-; Pax3GFP/+ mice (2). Lesions are 
histologically indistinguishable among groups. Bars: (e) 200µm; (f) 50µm and 5mm (insert); 
(g) 100µm. h: Kaplan-Meier of melanoma-free survival curves in Tyr::NRASQ61K; Cdkn2a-/-; 
Pax3GFP/+ (dashed line) and in control mice (plain line), i-j: Pax3 mRNA (i) and PAX3 
protein (j) levels in primary melanomas from Tyr::NRASQ61K; Cdkn2a-/-; Pax3GFP/+ (grey) and 
control mice (black). The ratio of PAX3/α-tubulin shows that tumors with the Pax3GFP/+ allele 
develop with half of PAX3 protein levels (1.1±0.08 versus 0.51±0.04).  
  
Figure 3. Pax3GFP allele and melanoma cells identification based on GFP 
a: ApoTome microscopy analysis of GFP direct fluorescence (green), mostly nuclear (blue) in 
epidermis (a1, a2) or melanoma sections (b1-b3) of Tyr::NRASQ61K; Cdkn2a-/-; Pax3GFP/+ 
mice. Bar a: 10µm, Bar b: 20µm c-d: ApoTome microscopy analysis of double labeling for 
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PAX3 (1, green) and GFP (2, magenta) in control (c) and Tyr::NRASQ61K; Cdkn2a-/-; 
Pax3GFP/+ (d) melanoma sections. Nuclear counterstaining in blue. Corresponding bright-field 
photographs (a2, b3, c5, d5). The PAX3 signal is nuclear whereas the GFP signal is both 
nuclear and cytoplasmic. Bar: 10µm. 
 
Figure 4. Characterization of FACS-sorted melanoma cells.  
a: Primary culture of primary melanoma, loco-regional metastasis and distant metastasis from 
Tyr::NRASQ61K; Cdkn2a-/-; Pax3GFP/+ mice showing phenotypic and pigmentation 
heterogeneity in FACS-sorted cells, b: Photomicrographs of a soft agar assay of primary cells 
during melanoma progression, c: Photomicrographs of primary culture cells subjected to the 
modified Boyden chamber assay, cell quantification, d: Fluorescent microscopy of lung 
metastases sections in syngeneic mice 15 days after retro-orbital injection of the type of 
primary culture cells indicated. 
 
Haplosufficiency of PAX3 for melanoma development in Tyr::NRASQ61K; Cdkn2a-/- 
mice allows identification and sorting of melanoma cells using a Pax3GFP reporter 
allele 
Campagne C et al.  
 
Supplementary Materials  
Mice genotyping 
To identify the Pax3GFP transgene, the GFP sequence was amplified using the following 
primers: GFP forward: 5’-ttgtggcggatcttgaagttcaccttgatgc-3’; GFP reverse: 5’-
acatgaagcagcacgacttcttcaagtccg-3’. PCR conditions were 30 s at 94°C, 30 s at 57°C, 40 s 
at 72°C for 35 cycles. Pax3GFP/+ pups could also be identified by direct detection of 
fluorescent GFP+ cells on the snout. The primers used to identify the NRASQ61K were: 
NRAS forward: 5’-gatvvvaccatagagggatt-3’; NRAS reverse: 5’- ctggcgtatttctcttacc-3’. 
PCR conditions were 1 min at 94°C, 1 min at 56°C, 1 min at 72°C for 4 cycles; 30s at 
94°C, 30s at 56°C, 30s at 72°C for 30 cycles. The hyperpigmented phenotype was 
observed in Tyr::NRASQ61K pups from the first week onwards. The primers used to 
identify the Cdkn2a locus were: forward 5’- ctatcaggacatagcgttgg-3’ and reverse: 5’-
agtgagagtttggggacagag-3’. PCR conditions were 1min at 94°C, 1 min at 57°C, 1 min at 
72°C for 4 cycles; 30s at 94°C, 45s at 57°C, 30s at 72°C for 30 cycles. The primers used 
to identify the Cdkn2a deleted locus were: forward 5’-atgatgatgggcaacgttc-3’ and reverse: 
5’-gttcccagcggtacacaaag- 3’. PCR conditions were 1 min at 94°C, 1 min at 58°C, 1 min at 
72°C for 4 cycles; 30s at 94°C, 45s at 58°C, 30s at 72°C for 30 cycles. All PCR were 
completed with a final extension step at 72°C for 10 min. 
Primary antibodies used for immunofluorescence in mice samples.  
Immunofluorescence was performed with chicken polyclonal anti-GFP (1: 600, Abcam, 
Paris, France), rabbit polyclonal anti-PAX3 (1:100, Zymed, Invitrogen, Cergy-Pontoise, 
France), mouse monoclonal anti-PAX3 (1:200, Developmental Studies Hybridoma Bank, 
Iowa university, Iowa, USA) and rabbit polyclonal anti-pERK (phospho-p42/44 MAPK, 
1:100, Cell Signaling, Ozyme, St Quentin, France) antibodies. Nuclear counter-staining 
was achieved with 4', 6'-diamidino-2-phenylindole (DAPI) (1:1000, Invitrogen). Controls 
without the first antibodies showed no unspecific labeling.  
qPCR primers. qPCR primers were as follows. PAX3: 5’-tgggcagtatggacaaagtg-3’ and 
5’-gtggaggccggaaacagg-3’ and housekeeping gene β-actin: 5‘-tccacacccgccaccagttc-3’ 
and 5’-gacccattcccaccatcacacc-3’, and cyclophilinA: 5’-caaatgctggaccaaacacaa-3′ and 5′-
ccatccagccattcagtcttg-3′. qPCR experiments were carried out at least twice in triplicates. 
	  
 
Supplementary Figures 
Figure S1. Phospho-ERK staining in melanoma sections. 
a-b: ApoTome microscopy analysis of double labeling for pERK (1, green) and Pax3 (a2, 
red) or GFP (b2, red) in control (a) and Tyr::NRASQ61K; Cdkn2a-/-; Pax3GFP/+ (b) 
melanoma sections. Nuclear counterstaining in blue (3). Corresponding bright-field 
photographs (5). Bar: 10µm. 
 
Figure S2. Phospho-ERK staining in FACS-sorted melanocytes and melanoma cells. 
ApoTome microscopy analysis of pERK labeling in FACS-sorted melanocytes and 
melanoma cells at different stages of melanoma progression. Bars: 10µm.  
	  


